Activating mutations in catalytic subunit PIK3CB alters the interaction between p110 and p85 subunits and confers resistance to the pan-PI3K inhibitor; such resistance could be overcome by applying downstream inhibitors targeting AKT or mTOR complexes by way of experiments in the PTEN-depletion BC cell line [28]. This evidence concerns the gene PIK3R2 and breast cancer.